Clinical trials recruiting in Guangdong, China

Phase breakdown

Conditions recruiting in Guangdong, China

Recruiting trials in Guangdong, China

• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
  NCT06764615 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
  NCT06970639 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
  NCT05461768 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of HLX42 in Advanced/Metastatic Solid Tumors
  NCT06210815 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients
  NCT06542016 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• China Colorectal Cancer Screening Trial 1 (C-Cost1)
  NCT07090291 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 74 Years · Sex: All (male and female)
• Chinese Psoriasis Real World Evidence Research
  NCT04465838 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
  NCT06809764 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
  NCT07610720 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female
• Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD)
  NCT07073066 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 80 Years · Sex: All (male and female)
• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
  NCT05891093 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female
• Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
  NCT06597201 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
  NCT06924606 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Lecanemab for Early Onset Familial Alzheimer's Disease
  NCT06883019 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
  NCT06095583 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
  NCT05794971 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
  NCT05909332 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female
• This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
  NCT06862206 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Guangdong, China?

20 recruiting trials have at least one study site in Guangdong, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.